Clearside Biomedical Inc (CLSD) Receives $11.83 Average PT from Brokerages

Share on StockTwits

Shares of Clearside Biomedical Inc (NASDAQ:CLSD) have been assigned a consensus rating of “Hold” from the eleven brokerages that are presently covering the firm, MarketBeat Ratings reports. Two analysts have rated the stock with a sell rating, three have issued a hold rating and six have given a buy rating to the company. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $11.83.

A number of analysts recently commented on the company. Zacks Investment Research lowered Clearside Biomedical from a “hold” rating to a “sell” rating in a research note on Tuesday, October 9th. Wedbush set a $29.00 price target on Clearside Biomedical and gave the stock a “buy” rating in a research note on Tuesday, October 23rd. JPMorgan Chase & Co. lowered Clearside Biomedical from an “overweight” rating to an “underweight” rating in a research note on Monday, November 5th. Cowen lowered Clearside Biomedical from an “outperform” rating to a “market perform” rating in a research note on Monday, November 5th. Finally, Stifel Nicolaus reaffirmed a “hold” rating and issued a $4.00 price target (down previously from $20.00) on shares of Clearside Biomedical in a research note on Monday, November 5th.

Shares of Clearside Biomedical stock opened at $1.21 on Friday. The company has a current ratio of 4.59, a quick ratio of 4.59 and a debt-to-equity ratio of 0.22. Clearside Biomedical has a 52-week low of $0.99 and a 52-week high of $15.33. The company has a market capitalization of $37.79 million, a PE ratio of -0.52 and a beta of -1.80.

Clearside Biomedical (NASDAQ:CLSD) last issued its earnings results on Thursday, November 8th. The company reported ($0.75) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.63) by ($0.12). As a group, analysts predict that Clearside Biomedical will post -2.57 EPS for the current year.

Institutional investors have recently made changes to their positions in the business. BlackRock Inc. lifted its position in Clearside Biomedical by 53.1% during the second quarter. BlackRock Inc. now owns 1,859,948 shares of the company’s stock valued at $19,883,000 after buying an additional 645,292 shares during the period. Voya Investment Management LLC purchased a new position in Clearside Biomedical during the second quarter valued at $123,000. Point72 Asset Management L.P. purchased a new position in Clearside Biomedical during the second quarter valued at $2,138,000. Northern Trust Corp lifted its position in Clearside Biomedical by 28.1% during the second quarter. Northern Trust Corp now owns 311,755 shares of the company’s stock valued at $3,333,000 after buying an additional 68,357 shares during the period. Finally, GSA Capital Partners LLP purchased a new position in Clearside Biomedical during the second quarter valued at $534,000. 57.94% of the stock is owned by institutional investors and hedge funds.

About Clearside Biomedical

Clearside Biomedical, Inc, a late-stage clinical biopharmaceutical company, develops pharmacological therapies to treat blinding diseases of the eye. It is developing suprachoroidal injection of CLS-TA, a proprietary preservative-free formulation of the corticosteroid triamcinolone acetonide, which is in Phase III clinical trial for the treatment of macular edema associated with non-infectious uveitis; suprachoroidal injection of CLS-TA and a concomitant intravitreal injection of Eylea, an inhibitor of vascular endothelial growth factor that is in Phase III clinical trial to treat macular edema associated with retinal vein occlusion; and suprachoroidal injection of CLS-TA alone or together with intravitreal injection of Eylea that is in phase II clinical trial for diabetic macular edema.

Further Reading: Tariff

Analyst Recommendations for Clearside Biomedical (NASDAQ:CLSD)

Receive News & Ratings for Clearside Biomedical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clearside Biomedical and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2019 BBNS.